Which Companies Lead the Generalized Myasthenia Gravis Treatment (gMG) Market in 2026?

DataM Intelligence has published its latest research report, "Generalized Myasthenia Gravis Treatment Market Size 2026." The report provides comprehensive analysis of market dynamics, including regional growth patterns, segment-wise performance, CAGR forecasts, competitive positioning, and revenue trends across key industry participants. It also examines the major factors influencing market expansion, emerging business opportunities, and strategic developments. Designed to support informed business planning, the study delivers a clear assessment of market value, volume, and future growth prospects within the global Generalized Myasthenia Gravis Treatment market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/generalized-myasthenia-gravis-treatment-market?kb

United States: Recent Industry Developments

✅ May 2026: argenx received U.S. FDA approval to expand VYVGART® and VYVGART Hytrulo® for all adult patients with generalized myasthenia gravis (gMG), including anti-AChR, anti-MuSK, anti-LRP4, and triple-seronegative subtypes.

✅ April 2026: Johnson & Johnson presented over two years of Phase 3 data showing sustained disease control with IMAAVY® (nipocalimab) and initiated the EPIC head-to-head study against another FcRn inhibitor for gMG.

✅ January 2026: Kyverna Therapeutics enrolled the first patient in its registrational Phase 3 trial evaluating KYV-101 CAR-T cell therapy for generalized myasthenia gravis.

✅ January 2026: DelveInsight highlighted strong momentum in the gMG treatment pipeline, driven by advancing late-stage immunotherapies including Descartes-08, FABHALTA (iptacopan), and Claseprubart (DNTH103).

Ready to get in the Generalized Myasthenia Gravis Treatment Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/generalized-myasthenia-gravis-treatment-market?kb

List of Key Players 2026:

Alexion Pharmaceuticals, Inc., Argenx, and UCB S.A. The emerging companies include Amgen Inc., Kyverna Therapeutics, Novartis AG, RemeGen Co., Ltd., Cartesian Therapeutics, Dianthus Therapeutics, Immunovant Sciences GmbH, Momenta Pharmaceuticals, Inc., Merck KGaA, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc., Takeda, Janssen Research & Development, LLC, Cabaletta Bio, COUR Pharmaceutical Development Company, Inc., Juno Therapeutics, Inc., Arcellx, Inc.

Key Developments 2025-2026:

In May 2026, argenx SE announced that the U.S. FDA approved an expanded indication for VYVGART® and VYVGART Hytrulo®, making them the first FcRn inhibitors approved for all adult patients with generalized myasthenia gravis (gMG), regardless of antibody status.

In May 2026, Johnson & Johnson announced that China's National Medical Products Administration (NMPA) approved nipocalimab for the treatment of generalized myasthenia gravis (gMG) in patients aged 12 years and older, expanding the therapy's global footprint.

In January 2026, Kyverna Therapeutics announced the enrollment of the first patient in its registrational Phase III clinical trial evaluating KYV-101 CAR-T cell therapy for patients with generalized myasthenia gravis (gMG).

In January 2026, Vertex Pharmaceuticals initiated a Phase II proof-of-concept clinical study evaluating povetacicept as a potential treatment for generalized myasthenia gravis, expanding its autoimmune disease pipeline.

How Our Market Research Process Works:

The global Generalized Myasthenia Gravis Treatment Market research report is built on a robust blend of primary and secondary research methodologies. The study provides detailed analysis of key market influences, including regulatory frameworks, shifting industry dynamics, competitive landscapes, and historical market performance. It further examines technological progress, emerging innovations, and developments across adjacent sectors. Additionally, the report evaluates growth potential, market uncertainties, operational challenges, and emerging opportunities that are expected to shape the future trajectory of the global Generalized Myasthenia Gravis Treatment market.

Recent Mergers & Acquisitions (M & A) 2025-2026:

• February 2026: Gilead Sciences agreed to acquire Arcellx for up to US$7.8 billion, adding autoimmune pipeline assets, including a preclinical generalized myasthenia gravis (gMG) program, alongside its oncology portfolio.

Request Strategic Market Customization: https://datamintelligence.com/customize/generalized-myasthenia-gravis-treatment-market?kb

Japan: Recent Industry Developments

✅ May 2026: Johnson & Johnson announced China approval of nipocalimab, following earlier approvals in Japan, further strengthening its commercialization strategy across Asia-Pacific for generalized myasthenia gravis.

✅ April 2026: Johnson & Johnson shared long-term Phase 3 evidence demonstrating sustained efficacy of IMAAVY® (nipocalimab) in antibody-positive gMG patients, supporting continued adoption in Japan and other global markets.

✅ January 2026: Japan's pharmaceutical outlook identified several rare disease therapies, including generalized myasthenia gravis candidates, among priority approvals expected during 2026 under the country's accelerated regulatory pathway.

✅ January 2026: Japanese regulatory focus on innovative orphan and autoimmune therapies continued to support market access for next-generation biologics and immunotherapies targeting generalized myasthenia gravis.

Major Focused Key Segmentations 2026:

By Treatment Type: Monoclonal Antibodies, Eculizumab (Soliris), Ravulizumab (Ultomiris), Efgartigimod (Vyvgart), Rozanolixizumab-noli (Rystiggo), Cholinesterase Inhibitors, Corticosteroids, Prednisone, Methylprednisolone, Immunosuppressants, Azathioprine, Mycophenolate mofetil, Cyclosporine, Methotrexate, Plasma Exchange (Plasmapheresis), Intravenous Immunoglobulin (IVIg), Others

By Route of Administration: Oral, Intravenous, Subcutaneous, Others

Regional Growth Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

We Provide Benefits of the Report:

Chapter 1: Establishes the report framework by outlining market scope, key segments by region, product type, and application. It provides a comprehensive overview of current market size, growth outlook, and projected industry development across short-, medium-, and long-term horizons.

Chapter 2: Highlights the most influential market findings, examining the major trends, opportunities, and forces driving industry transformation and future growth.

Chapter 3: Delivers an in-depth assessment of the competitive environment, including market share analysis, strategic developments, partnerships, and mergers & acquisitions influencing industry dynamics.

Chapter 4: Profiles leading market participants with detailed insights into financial performance, product offerings, business strategies, profitability, and significant corporate developments.

Chapters 5 & 6: Provide comprehensive revenue analysis at regional and country levels, identifying market size, growth trends, investment hotspots, and emerging expansion opportunities worldwide.

Chapter 7: Examines the market by product category, uncovering segment-level performance trends and highlighting promising areas for future growth and investment.

Chapter 8: Evaluates the market by application, analyzing demand patterns across end-use industries and identifying sectors expected to generate substantial growth opportunities.

Chapter 9: Offers a detailed overview of the industry value chain, covering upstream suppliers, downstream consumers, and key processes that influence market development.

Chapter 10: Concludes with a strategic summary of the report's most important findings, market opportunities, and actionable insights shaping the industry's future direction.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=generalized-myasthenia-gravis-treatment-market?kb

gMG Clinical Trials 2026 Update

RESET-MG is a key ongoing study of Cabaletta Bio's rese-cel, with 2026 results expected from this Phase 1/2 trial in adults with generalized myasthenia gravis.

Novartis has an active gMG study listed in 2026, reflecting continued late-phase development in the FcRn and autoimmune treatment space.

The Myasthenia Gravis Foundation of America continues to track multiple recruiting trials for adult and pediatric patients, showing that enrollment activity remains strong in 2026.

FAQ

Q1: What is the current valuation of the Generalized Myasthenia Gravis Treatment Market?

A: The Generalized Myasthenia Gravis Treatment Market was valued at US$ 3.78 billion in 2024 and is anticipated to reach US$ 15.57 billion by 2033, reflecting strong growth potential across key industry segments.

Q2: What is the projected growth rate of the Generalized Myasthenia Gravis Treatment Market?

A: The Generalized Myasthenia Gravis Treatment Market is expected to expand at a CAGR of 17.1% from 2025 to 2033, driven by increasing demand, evolving consumer preferences, and expanding application areas.

gMG 2026 FDA Treatment Updates

In May 2026, the FDA expanded VYVGART and VYVGART Hytrulo to cover all adult generalized myasthenia gravis serotypes, including anti-AChR, anti-MuSK, anti-LRP4, and triple-seronegative patients.

The expansion was supported by the Phase 3 ADAPT SERON study, which showed clinically meaningful improvement in MG-ADL versus placebo at four weeks.

In 2025, the FDA approved IMAAVY (nipocalimab) for gMG in adults and pediatric patients age 12 and older with anti-AChR or anti-MuSK antibodies, marking another major FcRn-blocker approval.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.